Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    ALX Oncology Holdings Inc. (ALXO) Insider Trading Activity

    Healthcare • Biotechnology • 81 employees

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

    Total Value

    $5,502.55

    Total Shares

    8,739

    Average Trade Value

    $611.39

    Most Active Insider

    Hemrajani Rekha

    Total Activity: $46,404

    Largest Single Transaction

    $46,404

    by Hemrajani Rekha on Dec 2, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Interim CFO
    Jan 6, 2025 2,221 $3,998 87,902 (-2.5%) Sale
    President Cso
    Dec 30, 2024 10,796 $17,060 580,714 (-1.9%) Sale
    Interim CFO
    Dec 30, 2024 1,426 $2,253 90,123 (-1.6%) Sale
    Dec 2, 2024 30,000 $46,404 33,000 (+90.9%) Purchase
    President Cso
    Aug 14, 2024 1,937 $4,997 591,510 (-0.3%) Sale
    Chief Executive Officer
    Aug 14, 2024 2,191 $5,653 169,429 (-1.3%) Payment of Exercise Price
    Chief Medical Officer
    Aug 14, 2024 1,365 $3,522 325,711 (-0.4%) Sale
    Svp, Finance and Cao
    Aug 14, 2024 564 $1,455 91,549 (-0.6%) Sale
    Chief Financial Officer
    Aug 14, 2024 761 $1,963 121,516 (-0.6%) Payment of Exercise Price